Table 1.
Baseline Characteristics of Study Subjects.
| Variable | Testosterone (82) | Placebo (84) |
|---|---|---|
| Age (y) | 74±6 | 74±5 |
| BMI (kg/m2) | 29.8±4.1 | 30.1±4.4 |
| Diabetes | 21 (26%) | 26 (31%) |
| Hyperlipidemia | 53 (65%) | 42 (50%) |
| Statin use | 53 (65%) | 39 (46%) |
| Smoking status | ||
| Current | 6 (7.4%) | 6 (7.1%) |
| Former | 55 (68%) | 58 (69%) |
| Never | 20 (25%) | 20 (24%) |
| Hemoglobin (g/dL) | 14.0±1.2 | 13.9±1.3 |
| Hematocrit (%) | 41.1±3.5 | 40.8±3.6 |
| Hepcidin (ng/mL) | 89±54 | 102±65 |
| Iron (mcg/dL) | 150±72 | 154±88 |
| IBC (mcg/dL) | 392±85 | 391±107 |
| TSAT (%) | 37±12 | 38±11 |
| Ferritin (ng/dL) | 115±79 | 132±97 |
| EPO (mIU/mL) | 13.5±11.9 | 11.7±6.6 |
| Total testosterone (ng/dL) | 252±56 | 236±63 |
| Free testosterone (ng/dL) | 4.8±2.6 | 4.3±1.7 |
| Estrone (pg/mL) | 35±18 | 31±13 |
| Estradiol (pg/mL) | 22±10 | 21±9 |
| Interleukin-6 (pg/mL) | 3.2±2.4 | 4.2±4.3 |
| sTR (nmol/L) | 19.2±5.2 | 21.9±10.4 |
| WBC (1000/µL) | 7.0±1.5 | 7.1±1.8 |
| MCV (fL) | 93.0±4.2 | 91.6±6.3 |
| MCHC (g/dL) | 34±0.9 | 34±0.8 |
| Lymphocytes (%) | 23.4±9.2 | 26.9±12.2 |
| Platlet (1000/µL) | 214±63 | 209±57 |
| RDW (%) | 13.9±1.1 | 14.0±1.5 |
| RBC (million/μL) | 4.42±0.43 | 4.43±0.72 |
| sTR/log hepcidin | 10.6±3.3 | 11.3±4.7 |
| sTR/log ferritin | 10.1±3.0 | 10.7±4.6 |
Notes: BMI = body mass index; EPO = erythropoietin; IBC = iron binding capacity; MCHC = mean corpuscular hemoglobin concentration; MCV = mean corpuscular volume; RBC = red blood cell; RDW = red cell distribution width; sTR = soluble transferrin receptor; TSAT = transferrin saturation; WBC = white blood cell.